Developer docs
API playgroundTry for free, no card

Search company profiles

EverythingALS

Full company profile

uuid0000ufk

Namestring
EverythingALS
Legal namestring
Peter Cohen Foundation
Company typeenum
Private
Founded yearint
2020
Descriptiontext

EverythingALS is a patient-focused nonprofit 501(c)(3) organization, operating as a brand of the Peter Cohen Foundation, that applies AI and data science to ALS across the care-to-cure continuum. Founded in 2020 and headquartered in Seattle with 11-50 employees, the organization serves people with ALS (pALS), caregivers (cALS), academic researchers, and biopharmaceutical companies through an open-data platform whose community spans 44 countries. Core offerings include SAVA AI (AI-powered clinical trial matching with reported 92% accuracy), the EverythingALS Mobile App, the ALS Motor App (self-administered assessment of 46 motor tasks), the ECAS Copilot (AI-assisted cognitive screening with live transcription), and NeuroLens (digital diagnostic for early detection in pre-symptomatic gene carriers, in development with Massachusetts General Hospital).

The technical stack combines speech analysis (OpenSMILE-based acoustic features; up to 90% AUC for ALS stage distinction), computer vision for facial metrics, NLP (Whisper OpenAI transcription, Bing query analysis at AUC 0.81), and multi-omics machine learning. These capabilities were developed in collaboration with MIT, MGH, UT Austin, Google, Gladstone Institute, and AnswerALS. Revenue comes exclusively from tax-deductible donations and research grants (~$1.4M disclosed to date, including a $400K grant in August 2023 and a $1M co-investment in the Allen Institute's Brain Health Accelerator in June 2026); all patient-facing products are free. Go-to-market is community-led and event-driven, executed through bi-monthly virtual Expert Talks, Citizen Research sessions, Fireside Chats, a Pathfinders advocate program, and a multi-channel social presence.

Short descriptiontext

EverythingALS is a Seattle-based 501(c)(3) nonprofit that uses AI and an open-data platform to connect ALS patients, caregivers, researchers, and drug companies across 44 countries, offering clinical trial matching (SAVA AI), speech and motor assessment apps, and research data infrastructure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ALS patient support, clinical trial matching, neurological disease research, open data platform, speech analysis tools
Industry2 codes
PRIMARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAK
Home Diagnostics & At-Home Testing Connectivity Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Digital Health Research Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Donations and Charitable Contributions
TypeGrants Donations
Description

EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3) organization (EIN 84-3055901). 100% of donations are applied to help people with ALS directly with their expenses and ALS research. Donations are tax-deductible.

everythingals.org
2Grant Funding
TypeProfessional Services
Description

The organization receives grant funding for specific research projects, such as the $400,000 grant from businesswire for NeuroLens development with Massachusetts General Hospital.

businesswire.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details2 tiers
1Free access to SAVA AI clinical trial matching platform
ModelFreemiumBilling cadenceMonthly
Notes

SAVA AI is available for free to ALS patients to match with clinical trials

alsnewstoday.com
2Free mobile app access
ModelFreemiumBilling cadenceMonthly
Notes

EverythingALS App available free on Google Play and Apple App Store

everythingals.org
GTM typeB2C
B2C
Offering typeSoftware
Software
Brand1 of 2 records shown
1SAVA AI
Description

AI-powered online tool that matches amyotrophic lateral sclerosis (ALS) patients with clinical trials by analyzing their health data against eligibility requirements, achieving 92% accuracy rate.

alsnewstoday.com
+1 more record
Core offering1 text field

EverythingALS is a patient-focused nonprofit that provides a suite of digital health tools and an open-data platform for ALS care, research, and clinical trial engagement. Core offerings include the SAVA AI clinical trial matching tool, the EverythingALS mobile application, the ALS Motor App for remote motor assessment, the ECAS Copilot for AI-assisted cognitive screening, the Open Data Platform for research collaboration, and the in-development NeuroLens digital diagnostic tool.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 92% accuracy rate in identifying relevant clinical trials
+2 more records
Product overview1 text field

EverythingALS is a patient-focused nonprofit offering a platform of digital health tools and open-data resources for ALS care and research. The core portfolio includes the EverythingALS Mobile App and Open Data Platform for patient engagement and data sharing; SAVA AI for AI-powered clinical trial matching; the ALS Motor App for remote motor assessment; the ECAS Copilot for AI-assisted cognitive screening; and NeuroLens (in development) as a digital diagnostic tool for early detection. The organization also hosts Expert Talks and community events. The platform processes speech, video, and structured clinical data using machine learning and NLP to support early detection, disease monitoring, and clinical trial recruitment.

Product and service2 records
1SAVA AI
CategoryClinical Trial Matching
Description

AI-powered online tool that matches ALS patients with clinical trials by analyzing their health data against eligibility requirements. Reports a 92% accuracy rate in identifying relevant studies and can connect patients to suitable trials in seconds. Free for ALS patients.

2EverythingALS Mobile App
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-22
Description

EverythingALS hosted a virtual community event on June 24, 2026 to discuss emerging clinical data on PrimeC, NeuroSense's investigational ALS treatment. Prof. Jeffrey Rosenfeld from Loma Linda University and NeuroSense CEO Alon Ben-Noon led the discussion focused on ALS patients, families, caregivers, and clinicians.

2Vision 2030
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

EverythingALS and Vision 2030 announced a $1M initial investment in the Allen Institute's newly launched Brain Health Accelerator to accelerate ALS research. The ALS Network and The Head Cook for ALS also made additional contributions, with amounts multiplied up to 5:1 by the Allen Institute's infrastructural and ALS-related allocations.

businesswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Allen Institute launched the Brain Health Accelerator with $400 million in funding aimed at developing gene therapies for neurodegenerative diseases including ALS. EverythingALS and Vision 2030 invested $1M initial investment in this initiative, with ALS as the first disease studied under the accelerator.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-22
Description

EverythingALS.org and Massachusetts General Hospital received a $400,000 grant to develop NeuroLens, a digital diagnostic tool for early detection of ALS. The project involves digital monitoring of pre-symptomatic gene carriers to identify early signs of ALS and improve diagnosis speed.

5MIT
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with MIT on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.

everythingals.org
6UT Austin
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with UT Austin on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.

everythingals.org
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration with Google on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Supporting Gladstone Institute with multi-omics analysis with machine learning and big data to uncover ALS causes, subtypes, pathways, and drug targets.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Supporting AnswerALS with multi-omics analysis with machine learning and big data to uncover ALS causes, subtypes, pathways, and drug targets.

10VectorY Therapeutics
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with VectorY Therapeutics as part of historic ALS investment momentum, with VectorY dosing first patient in its ALS trial.

biospace.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Patient-focused nonprofit conducting ALS research with its own lab and data programs. Directly comparable as an ALS-focused nonprofit investing in technology and data science to accelerate cures.

TypeDirect peer
Description

Multi-institution ALS research program that EverythingALS already supports. Comparable as an ALS data and research platform aggregating patient data and biosamples for scientific collaboration.

TypeBroad incumbent
Description

Largest US ALS nonprofit providing care services, advocacy, and research funding. Overlaps with EverythingALS on patient support, clinical trial awareness, and research funding, but operates at far greater scale with a broader portfolio.

TypeDirect peer
Description

Nonprofit led by former chairman of The ALS Association that co-led EverythingALS's $400K NeuroLens grant. Comparable as an ALS-focused research funder and grant-maker supporting clinical and translational projects.

5Project ALS
TypeDirect peer
Description

Patient-driven nonprofit funding ALS research at leading institutions. Comparable in mission and operating model (small nonprofit funding ALS research with patient focus) though less technology-led.

TypeBroad incumbent
Description

Large nonprofit covering ALS along with dozens of neuromuscular diseases. Comparable in patient services and research funding, but with a much broader disease portfolio and deeper institutional resources.

7Healey Center for ALS at Massachusetts General Hospital
TypeDirect peer
Description

Major academic ALS clinical and research center where EverythingALS has co-developed NeuroLens. Comparable in driving ALS platform trials, biomarker development, and clinical trial recruitment.

TypeDirect peer
Description

Patient-led ALS advocacy nonprofit focused on community organizing, policy, and research funding. Comparable as a grassroots, patient-driven ALS nonprofit, though less focused on AI and digital biomarkers.

9NEALS Consortium
TypeOthers
Description

Network of ALS clinical trial sites collaborating on trial design and execution. Comparable as an ecosystem partner that EverythingALS could feed patients into via SAVA AI matching.

TypeOthers
Description

Biopharmaceutical company with a marketed ALS therapy (Qalsody). Thematically comparable as a major pharma player whose clinical trial recruitment needs EverythingALS's SAVA AI platform is positioned to address.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EverythingALS

Digital Health Research Platformeverythingals.org

EverythingALS is a Seattle-based 501(c)(3) nonprofit that uses AI and an open-data platform to connect ALS patients, caregivers, researchers, and drug companies across 44 countries, offering clinical trial matching (SAVA AI), speech and motor assessment apps, and research data infrastructure.

What EverythingALS does

EverythingALS is a patient-focused nonprofit 501(c)(3) organization, operating as a brand of the Peter Cohen Foundation, that applies AI and data science to ALS across the care-to-cure continuum. Founded in 2020 and headquartered in Seattle with 11-50 employees, the organization serves people with ALS (pALS), caregivers (cALS), academic researchers, and biopharmaceutical companies through an open-data platform whose community spans 44 countries. Core offerings include SAVA AI (AI-powered clinical trial matching with reported 92% accuracy), the EverythingALS Mobile App, the ALS Motor App (self-administered assessment of 46 motor tasks), the ECAS Copilot (AI-assisted cognitive screening with live transcription), and NeuroLens (digital diagnostic for early detection in pre-symptomatic gene carriers, in development with Massachusetts General Hospital).

The technical stack combines speech analysis (OpenSMILE-based acoustic features; up to 90% AUC for ALS stage distinction), computer vision for facial metrics, NLP (Whisper OpenAI transcription, Bing query analysis at AUC 0.81), and multi-omics machine learning. These capabilities were developed in collaboration with MIT, MGH, UT Austin, Google, Gladstone Institute, and AnswerALS. Revenue comes exclusively from tax-deductible donations and research grants (~$1.4M disclosed to date, including a $400K grant in August 2023 and a $1M co-investment in the Allen Institute's Brain Health Accelerator in June 2026); all patient-facing products are free. Go-to-market is community-led and event-driven, executed through bi-monthly virtual Expert Talks, Citizen Research sessions, Fireside Chats, a Pathfinders advocate program, and a multi-channel social presence.

EverythingALS firmographics

Firmographics
Name
EverythingALS
Legal name
Peter Cohen Foundation
Website
https://everythingals.org
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
EverythingALS is a Seattle-based 501(c)(3) nonprofit that uses AI and an open-data platform to connect ALS patients, caregivers, researchers, and drug companies across 44 countries, offering clinical trial matching (SAVA AI), speech and motor assessment apps, and research data infrastructure.
Ownership category
akta.pro rank

EverythingALS industry classification

Industry
Product category
Digital Health Research Platform
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAK
Home Diagnostics & At-Home Testing Connectivity Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • ALS patient support
  • Clinical trial matching
  • Neurological disease research
  • Open data platform
  • Speech analysis tools

Where EverythingALS is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

EverythingALS business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Donations and Charitable Contributions: EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3) organization (EIN 84-3055901). 100% of donations are applied to help people with ALS directly with their expenses and ALS research. Donations are tax-deductible.
  2. Grant Funding: The organization receives grant funding for specific research projects, such as the $400,000 grant from businesswire for NeuroLens development with Massachusetts General Hospital.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree access to SAVA AI clinical trial matching platform
FreemiumMonthlyFree mobile app access

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

EverythingALS product offering

Product offering

Core offering

EverythingALS is a patient-focused nonprofit that provides a suite of digital health tools and an open-data platform for ALS care, research, and clinical trial engagement. Core offerings include the SAVA AI clinical trial matching tool, the EverythingALS mobile application, the ALS Motor App for remote motor assessment, the ECAS Copilot for AI-assisted cognitive screening, the Open Data Platform for research collaboration, and the in-development NeuroLens digital diagnostic tool.

Product overview

EverythingALS is a patient-focused nonprofit offering a platform of digital health tools and open-data resources for ALS care and research. The core portfolio includes the EverythingALS Mobile App and Open Data Platform for patient engagement and data sharing; SAVA AI for AI-powered clinical trial matching; the ALS Motor App for remote motor assessment; the ECAS Copilot for AI-assisted cognitive screening; and NeuroLens (in development) as a digital diagnostic tool for early detection. The organization also hosts Expert Talks and community events. The platform processes speech, video, and structured clinical data using machine learning and NLP to support early detection, disease monitoring, and clinical trial recruitment.

Differentiator

Problem solved

Functional benefit

Brands

  • SAVA AI: AI-powered online tool that matches amyotrophic lateral sclerosis (ALS) patients with clinical trials by analyzing their health data against eligibility requirements, achieving 92% accuracy rate.
  • NeuroLens

Products and services

  • SAVA AI AI-powered online tool that matches ALS patients with clinical trials by analyzing their health data against eligibility requirements. Reports a 92% accuracy rate in identifying relevant studies and can connect patients to suitable trials in seconds. Free for ALS patients.
  • EverythingALS Mobile App

Quantifiable outcome

  • 92% accuracy rate in identifying relevant clinical trials
  • +2 more outcomes

Companies that use EverythingALS

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

EverythingALS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature5 records

EverythingALS partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • NeuroSense TherapeuticsminorGTM or Marketing Partner · 22 June 2026EverythingALS hosted a virtual community event on June 24, 2026 to discuss emerging clinical data on PrimeC, NeuroSense's investigational ALS treatment. Prof. Jeffrey Rosenfeld from Loma Linda University and NeuroSense CEO Alon Ben-Noon led the discussion focused on ALS patients, families, caregivers, and clinicians.
  • Vision 2030coreStrategic or Co-development Partner · 2 June 2026EverythingALS and Vision 2030 announced a $1M initial investment in the Allen Institute's newly launched Brain Health Accelerator to accelerate ALS research. The ALS Network and The Head Cook for ALS also made additional contributions, with amounts multiplied up to 5:1 by the Allen Institute's infrastructural and ALS-related allocations.
  • Allen InstitutecoreStrategic or Co-development Partner · 2 June 2026Allen Institute launched the Brain Health Accelerator with $400 million in funding aimed at developing gene therapies for neurodegenerative diseases including ALS. EverythingALS and Vision 2030 invested $1M initial investment in this initiative, with ALS as the first disease studied under the accelerator.
  • Massachusetts General HospitalcoreStrategic or Co-development Partner · 22 August 2023EverythingALS.org and Massachusetts General Hospital received a $400,000 grant to develop NeuroLens, a digital diagnostic tool for early detection of ALS. The project involves digital monitoring of pre-symptomatic gene carriers to identify early signs of ALS and improve diagnosis speed.
  • MITcoreStrategic or Co-development PartnerCollaboration with MIT on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.
  • UT AustincoreStrategic or Co-development PartnerCollaboration with UT Austin on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.
  • GooglecoreTechnology or IntegrationCollaboration with Google on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.
  • Gladstone InstitutecoreStrategic or Co-development PartnerSupporting Gladstone Institute with multi-omics analysis with machine learning and big data to uncover ALS causes, subtypes, pathways, and drug targets.
  • AnswerALScoreStrategic or Co-development PartnerSupporting AnswerALS with multi-omics analysis with machine learning and big data to uncover ALS causes, subtypes, pathways, and drug targets.
  • VectorY TherapeuticsminorStrategic or Co-development PartnerCollaboration with VectorY Therapeutics as part of historic ALS investment momentum, with VectorY dosing first patient in its ALS trial.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

EverythingALS competitors and assessment

Company assessment

Direct peers

  • ALS Therapy Development Institute (ALS TDI): Patient-focused nonprofit conducting ALS research with its own lab and data programs. Directly comparable as an ALS-focused nonprofit investing in technology and data science to accelerate cures.
  • Answer ALS: Multi-institution ALS research program that EverythingALS already supports. Comparable as an ALS data and research platform aggregating patient data and biosamples for scientific collaboration.
  • ALS Finding a Cure: Nonprofit led by former chairman of The ALS Association that co-led EverythingALS's $400K NeuroLens grant. Comparable as an ALS-focused research funder and grant-maker supporting clinical and translational projects.
  • Project ALS: Patient-driven nonprofit funding ALS research at leading institutions. Comparable in mission and operating model (small nonprofit funding ALS research with patient focus) though less technology-led.
  • Healey Center for ALS at Massachusetts General Hospital: Major academic ALS clinical and research center where EverythingALS has co-developed NeuroLens. Comparable in driving ALS platform trials, biomarker development, and clinical trial recruitment.
  • I AM ALS: Patient-led ALS advocacy nonprofit focused on community organizing, policy, and research funding. Comparable as a grassroots, patient-driven ALS nonprofit, though less focused on AI and digital biomarkers.

Broad incumbents

  • The ALS Association: Largest US ALS nonprofit providing care services, advocacy, and research funding. Overlaps with EverythingALS on patient support, clinical trial awareness, and research funding, but operates at far greater scale with a broader portfolio.
  • Muscular Dystrophy Association (MDA): Large nonprofit covering ALS along with dozens of neuromuscular diseases. Comparable in patient services and research funding, but with a much broader disease portfolio and deeper institutional resources.

Others

  • NEALS Consortium: Network of ALS clinical trial sites collaborating on trial design and execution. Comparable as an ecosystem partner that EverythingALS could feed patients into via SAVA AI matching.
  • Biogen: Biopharmaceutical company with a marketed ALS therapy (Qalsody). Thematically comparable as a major pharma player whose clinical trial recruitment needs EverythingALS's SAVA AI platform is positioned to address.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

EverythingALS social profiles

Digital presence

EverythingALS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EverythingALS leadership team

Management profile

Number of profiles

Profiles2 records

EverythingALS funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EverythingALS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EverythingALS

What does EverythingALS do?

EverythingALS is a patient-focused nonprofit that provides a suite of digital health tools and an open-data platform for ALS care, research, and clinical trial engagement. Core offerings include the SAVA AI clinical trial matching tool, the EverythingALS mobile application, the ALS Motor App for remote motor assessment, the ECAS Copilot for AI-assisted cognitive screening, the Open Data Platform for research collaboration, and the in-development NeuroLens digital diagnostic tool.

Is EverythingALS a public or private company?

EverythingALS is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was EverythingALS founded?

EverythingALS was founded in 2020. It employs 11 to 50 people.

Where is EverythingALS based?

EverythingALS is headquartered in Seattle, United States, in the North America region.

How does EverythingALS make money?

Two revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are grant Funding.

Who are EverythingALS's main competitors?

Direct peers on record are ALS Therapy Development Institute (ALS TDI), Answer ALS, ALS Finding a Cure, Project ALS, Healey Center for ALS at Massachusetts General Hospital and I AM ALS. Broad incumbents are The ALS Association and Muscular Dystrophy Association (MDA). Others are NEALS Consortium and Biogen.

Does EverythingALS have an API?

No public API is recorded for EverythingALS.

What industry is EverythingALS in?

EverythingALS's product category is Digital Health Research Platform. Its primary akta.pro industry code is HLACAFAO, Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways), with a secondary code of HLACAFAK, Home Diagnostics & At-Home Testing Connectivity Platforms. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogEverythingALS and ALS United Partner to Expand National Coverage of ALS Clinical Trial Matching with SAVA AIEverythingALS and ALS United announced a partnership to expand access to SAVA AI, a clinical trial matching platform, by making it available on ALS United's national website and through local member sites. The collaboration will generate de-identified aggregate insights into trial search patterns and geographic gaps. Both organizations hope the insights will guide future advocacy and research efforts.FinancialContent Business PageEverythingALS and ALS United Partner to Expand National Coverage of ALS Clinical Trial Matching with SAVA AIEverythingALS and ALS United announced a partnership to expand access to SAVA AI, a clinical trial matching platform, making it available on ALS United's national website and through member organizations. The collaboration will generate de-identified aggregate insights into trial search patterns and geographic gaps. The partners hope these insights will guide future advocacy and research efforts.BioSpaceEverythingALS and Vision 2030 Announce Expanded International Scientific Advisory Board to Support ALS Research CollaborationEverythingALS and Vision 2030 expanded the Vision 2030 Scientific Advisory Board to include international ALS researchers, clinicians, and nonprofit leaders. The board will guide a collaboration with the Allen Institute's Brain Health Accelerator, which launched an ALS initiative using advanced neuroscience tools. The partnership aims to accelerate discovery and identify potential drug targets.FinancialContent Business PageEverythingALS and Vision 2030 Announce Expanded International Scientific Advisory Board to Support ALS Research CollaborationEverythingALS and Vision 2030 expanded the Vision 2030 Scientific Advisory Board, adding international ALS researchers and clinicians to guide collaboration with the Allen Institute's Brain Health Accelerator. The board aims to accelerate ALS research, identify drug targets, and strengthen coordination across the ALS community.WebProNewsShingles Shots, $5 Trillion Burdens and Cell-Level Fixes: The Urgent Case for Brain ProtectionThe global economic burden of brain disorders amounts to $5 trillion annually, projected to reach $16 trillion by 2030, driving urgent calls for preventive action amid demographic shifts that will halve the working-age to retiree ratio by 2050. The Allen Institute launched a $400 million Brain Health accelerator on June 2, backed by contributions from the Fund for Science and Technology, the Bezos family ($100 million), Amazon Web Services, the National Institutes of Health, and EverythingALS, targeting Alzheimer's, Parkinson's, and other neurodegenerative diseases at the cellular level. Research highlights the shingles vaccine as a low-cost intervention linked to roughly 20 percent lower dementia risk, while evidence shows age-adjusted dementia rates have already declined in wealthy nations through improved cardiovascular care, better education, and reduced smoking.PR NewswireEverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the DotsEverythingALS will host a community conversation on June 24, 2026, featuring Prof. Jeffrey Rosenfeld and NeuroSense Therapeutics CEO Alon Ben-Noon to discuss emerging data on NeuroSense's drug candidate PrimeC for ALS treatment. NeuroSense has received FDA clearance to initiate a pivotal Phase 3 clinical trial (PARAGON) for PrimeC, following positive Phase 2b data showing meaningful slowing of disease progression and a potential survival benefit. The event is targeted at people living with ALS, families, caregivers, clinicians, and anyone interested in ALS research developments.Stock TitanNeuroSense to join ALS event on PrimeC dataNeuroSense Therapeutics announced that EverythingALS will host a virtual community event on June 24, 2026 to discuss emerging clinical data on PrimeC, the company's investigational ALS treatment. Prof. Jeffrey Rosenfeld from Loma Linda University and NeuroSense CEO Alon Ben-Noon will lead the discussion focused on ALS patients, families, caregivers, and clinicians. NeuroSense has received FDA clearance to initiate a pivotal Phase 3 trial (PARAGON) in ALS, following positive Phase 2b data showing slowed disease progression and a potential survival benefit.Business Wire BlogEverythingALS and Vision 2030 Invest in Allen Institute Initiative to Accelerate ALS ResearchEverythingALS and Vision 2030 have invested $1M in the Allen Institute's newly launched Brain Health Accelerator to accelerate ALS research, with the Allen Institute committing $200M to the initiative. Additional contributions from ALS Network and The Head Cook for ALS will be leveraged up to 5:1 through the Institute's infrastructure and research allocations, creating one of the most heavily leveraged philanthropic commitments in ALS research history. ALS will be the first disease studied under the Brain Health Accelerator, which builds on the Allen Institute's foundational work in Alzheimer's disease.EIN PresswireAllen Institute launches Brain Health accelerator to transform understanding of brain disorders, develop new treatmentsThe Allen Institute launched the Brain Health accelerator, a global research initiative to accelerate understanding and treatments for brain disorders. The initiative has a $400M commitment, including $200M from the Allen Institute, $100M from the Bezos family, and $100M from AWS, NIH, and EverythingALS. It will initially target Alzheimer's, Parkinson's, Huntington's, Lewy body dementia, and ALS.